Tuesday, August 03, 2021 7:36:14 AM
Sorrento Gets Fed Go-Ahead to Test Myeloma Med
August 03 2021 - 06:39AM
TipRanks
Alert
Share On Facebook
Sorrento Therapeutics (NASDAQ: SRNE), a clinical-stage, antibody-centric biopharmaceutical company, received the go-ahead to commence the Phase 1 clinical trial for allogeneic anti-CD38 Dimeric Antigen Receptor (DAR)-T cell therapy. The U.S. Food and Drug Administration (FDA) has authorized Sorrento’s Investigational New Drug (IND) application for its proprietary DAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. Following the FDA approval, shares of Sorrento closed 1.6% higher on Monday. Sorrento has designed DAR-T technology to provide a significant advancement to the timeliness and potency of myeloma treatments. The treatment targets patient populations who have already undergone multiple rounds of chemotherapy, and are suffering from persistent disease, the company said.
https://www.tipranks.com/news/sorrento-gets-fed-go-ahead-to-test-myeloma-med?utm_source=advfn.com&utm_medium=referral
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM